Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology, and drug delivery markets. The Company"s platform technology is based on recombinant human hyaluronidase plus additional enzymes. Halozyme applies its technology to its proprietary programs and to partnerships with pharmaceutical companies.
Website: halozyme.com



Growth: Good revenue growth rate 27.1%, there is slowdown compared to average historical growth rates 60.4%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +42.1%. On average the margin is improving unsteadily. Gross margin is high, +77.3%. In the last quarter the company did not beat the estimated EPS, -2.1%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 31.8% higher than minimum and 32.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 6.2x by EV / Sales multiple , the company can be 20.7% overvalued

Insiders: For the last 3 months insiders sold company shares on $2.4 mln (-0.045% of cap.)

Key Financials (Download financials)

Ticker: HALO
Share price, USD:  (+0.2%)39.91
year average price 37.99  


year start price 31.00 2023-05-07

min close price 30.28 2023-05-08

max close price 44.03 2023-08-10

current price 39.91 2024-05-05
Common stocks: 131 927 000

Dividend Yield:  0.0%
FCF Yield LTM: -0.6%
EV / LTM EBITDA: 18.5x
EV / EBITDA annualized: 15.5x
Last revenue growth (y/y):  27.1%
Last growth of EBITDA (y/y):  38.7%
Historical revenue growth:  60.4%
Historical growth of EBITDA:  58.1%
EV / Sales: 7.8x
Margin (EBITDA LTM / Revenue): 42.1%
Fundamental value created in LTM:
Market Cap ($m): 5 265
Net Debt ($m): 1 177
EV (Enterprise Value): 6 442
Price to Book: 62.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-24Zacks Investment Research

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

2024-04-18Zacks Investment Research

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

2024-04-18Zacks Investment Research

Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know

2024-04-04Zacks Investment Research

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

2024-03-21Zacks Investment Research

Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?

2024-03-19Zacks Investment Research

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

2024-02-21Zacks Investment Research

Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag

2024-02-20Zacks Investment Research

Compared to Estimates, Halozyme Therapeutics (HALO) Q4 Earnings: A Look at Key Metrics

2024-02-20Zacks Investment Research

Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates

2024-02-14Zacks Investment Research

Halozyme Therapeutics (HALO) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol HALO HALO HALO HALO HALO HALO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-20 2023-11-06 2023-08-08 2023-05-09 2023-02-21 2022-11-08
acceptedDate 2024-02-20 16:07:29 2023-11-06 16:07:46 2023-08-08 16:10:02 2023-05-09 16:17:05 2023-02-21 16:27:38 2022-11-08 16:10:10
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 230M 216M 221M 162M 181M 209M
costOfRevenue 52M 55M 50M 35M 42M 47M
grossProfit 178M 161M 171M 127M 139M 162M
grossProfitRatio 0.773 0.746 0.773 0.783 0.768 0.774
researchAndDevelopmentExpenses 21M 17M 20M 18M 23M 17M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 38M 35M 39M 37M 38M 34M
otherExpenses 18M 20M 18M 18M 5M 27M
operatingExpenses 77M 73M 77M 73M 65M 78M
costAndExpenses 129M 128M 127M 108M 107M 126M
interestIncome 0 4M 0 0 0 0
interestExpense 5M 5M 4M 5M 5M 8M
depreciationAndAmortization 21M 20M 21M 18M 5M 29M
ebitda 122M 109M 115M 72M 79M 112M
ebitdaratio 0.529 0.503 0.521 0.442 0.436 0.538
operatingIncome 101M 88M 94M 54M 75M 83M
operatingIncomeRatio 0.439 0.409 0.427 0.332 0.411 0.399
totalOtherIncomeExpensesNet 5M 18M 3M -2M -4M -10M
incomeBeforeTax 101M 102M 93M 52M 71M 74M
incomeBeforeTaxRatio 0.440 0.471 0.421 0.322 0.390 0.353
incomeTaxExpense 16M 20M 18M 13M 13M 12M
netIncome 85M 82M 75M 40M 58M 62M
netIncomeRatio 0.371 0.379 0.338 0.244 0.318 0.295
eps 0.660 0.620 0.570 0.290 0.430 0.450
epsdiluted 0.650 0.610 0.560 0.290 0.420 0.440
weightedAverageShsOut 129M 132M 132M 135M 135M 137M
weightedAverageShsOutDil 131M 134M 134M 138M 139M 139M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol HALO HALO HALO HALO HALO HALO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-20 2023-11-06 2023-08-08 2023-05-09 2023-02-21 2022-11-08
acceptedDate 2024-02-20 16:07:29 2023-11-06 16:07:46 2023-08-08 16:10:02 2023-05-09 16:17:05 2023-02-21 16:27:38 2022-11-08 16:10:10
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 118M 274M 221M 96M 234M 147M
shortTermInvestments 218M 209M 127M 179M 129M 118M
cashAndShortTermInvestments 336M 483M 348M 276M 363M 266M
netReceivables 234M 217M 246M 195M 231M 233M
inventory 128M 129M 132M 108M 100M 103M
otherCurrentAssets 49M 49M 39M 37M 45M 51M
totalCurrentAssets 746M 879M 766M 615M 739M 653M
propertyPlantEquipmentNet 75M 75M 75M 78M 76M 37M
goodwill 417M 417M 417M 416M 409M 199M
intangibleAssets 473M 491M 511M 529M 547M 949M
goodwillAndIntangibleAssets 890M 907M 928M 945M 956M 1 148M
longTermInvestments 0 0 0 0 0 0
taxAssets 4M 13M 24M 36M 44M 0
otherNonCurrentAssets 18M 18M 18M 26M 27M 26M
totalNonCurrentAssets 987M 1 014M 1 045M 1 084M 1 102M 1 211M
otherAssets 0 0 0 0 0 0
totalAssets 1 733M 1 893M 1 810M 1 699M 1 842M 1 865M
accountPayables 12M 19M 10M 9M 18M 18M
shortTermDebt 32M 32M 0 0 13M 13M
taxPayables 963 000 18M 0 0 0 0
deferredRevenue -32M 667 000 842 000 3M 3M 4M
otherCurrentLiabilities 101M 63M 105M 80M 97M 74M
totalCurrentLiabilities 112M 115M 116M 92M 131M 109M
longTermDebt 1 499M 1 498M 1 496M 1 494M 1 493M 1 491M
deferredRevenueNonCurrent 0 2M 2M 2M 2M 3M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 29M
otherNonCurrentLiabilities 38M 28M 45M 45M 46M 1 623M
totalNonCurrentLiabilities 1 537M 1 528M 1 543M 1 542M 1 541M 1 658M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 32M 32M 0 0 0 0
totalLiabilities 1 649M 1 643M 1 659M 1 634M 1 672M 1 768M
preferredStock 0 0 0 0 0 0
commonStock 127 000 132 000 132 000 132 000 135 000 135 000
retainedEarnings 91M 222M 140M 66M 143M 86M
accumulatedOtherComprehensiveIncomeLoss -9M 1M -2M 24 000 -922 000 -2M
othertotalStockholdersEquity 2M 26M 12M 0 27M 13M
totalStockholdersEquity 84M 249M 151M 66M 170M 97M
totalEquity 84M 249M 151M 66M 170M 97M
totalLiabilitiesAndStockholdersEquity 1 733M 1 893M 1 810M 1 699M 1 842M 1 865M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 733M 1 893M 1 810M 1 699M 1 842M 1 865M
totalInvestments 218M 209M 127M 179M 129M 118M
totalDebt 1 499M 1 498M 1 496M 1 494M 1 506M 1 504M
netDebt 1 381M 1 223M 1 275M 1 398M 1 272M 1 357M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol HALO HALO HALO HALO HALO HALO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-20 2023-11-06 2023-08-08 2023-05-09 2023-02-21 2022-11-08
acceptedDate 2024-02-20 16:07:29 2023-11-06 16:07:46 2023-08-08 16:10:02 2023-05-09 16:17:05 2023-02-21 16:27:38 2022-11-08 16:10:10
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 85M 82M 75M 40M 58M 62M
depreciationAndAmortization 21M 23M 21M 20M 7M 29M
deferredIncomeTax 9M 10M 12M 4M 15M 26M
stockBasedCompensation 10M 9M 10M 8M 7M 7M
changeInWorkingCapital -26M 22M -48M 14M -5M -60M
accountsReceivables -17M 29M -51M 36M -8M -44M
inventory 1M 4M -25M -7M -3M -6M
accountsPayables 11M 0 0 -24M -5M 0
otherWorkingCapital -22M -10M 28M -5M 10M -10M
otherNonCashItems 3M -14M -1M 1M 817 000 6M
netCashProvidedByOperatingActivities 102M 132M 67M 87M 82M 70M
investmentsInPropertyPlantAndEquipment -3M -3M 2M -11M -2M -1M
acquisitionsNet 6M 81M 0 0 0 0
purchasesOfInvestments -21M -162M 0 -110M -30M 0
salesMaturitiesOfInvestments 16M 81M 53M 61M 20M 0
otherInvestingActivites -6M -81M 0 0 10M 0
netCashUsedForInvestingActivites -8M -83M 55M -60M -2M -1M
debtRepayment -13M 0 0 -13M -334M -447M
commonStockIssued 9M 4M 0 -1M 10M 0
commonStockRepurchased -252M 0 0 -150M -1000.000 -200M
dividendsPaid 0 0 0 -13M 0 0
otherFinancingActivites 20M 4M 0 13M 331M 635M
netCashUsedProvidedByFinancingActivities -250M 4M 2M -165M 6M -12M
effectOfForexChangesOnCash 0 0 0 0 0 0
netChangeInCash -156M 53M 124M -138M 87M 56M
cashAtEndOfPeriod 118M 274M 221M 97M 235M 148M
cashAtBeginningOfPeriod 274M 221M 97M 235M 148M 91M
operatingCashFlow 102M 132M 67M 87M 82M 70M
capitalExpenditure -3M -3M 2M -11M -2M -1M
freeCashFlow 100M 129M 68M 76M 80M 69M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-20 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-21 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-10 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-20 21:01 ET
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
2024-02-08 21:30 ET
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
2024-01-29 21:15 ET
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2024-01-18 13:30 ET
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
2024-01-16 13:15 ET
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2024-01-16 06:15 ET
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
2024-01-12 14:25 ET
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
2023-11-27 13:00 ET
Halozyme to Present at Upcoming Investor Conferences
2023-11-16 14:00 ET
Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis
2023-11-06 21:01 ET
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
2023-11-06 12:30 ET
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease
2023-10-30 22:35 ET
Halozyme To Report Third Quarter 2023 Financial and Operating Results
2023-10-19 11:15 ET
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma
2023-10-16 19:05 ET
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference
2023-10-16 12:00 ET
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery
2023-08-31 12:30 ET
Halozyme to Present at Upcoming Investor Conferences
2023-08-29 08:50 ET
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
2023-08-08 20:01 ET
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
2023-07-25 12:30 ET
Halozyme To Report Second Quarter 2023 Financial and Operating Results
2023-07-17 05:15 ET
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
2023-07-13 05:15 ET
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
2023-06-20 22:30 ET
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis
2023-06-06 12:30 ET
Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-09 20:01 ET
HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS
2023-05-03 12:30 ET
Halozyme to Present at Upcoming Investor Conferences
2023-04-25 12:30 ET
Halozyme To Report First Quarter 2023 Financial and Operating Results
2023-03-15 11:44 ET
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
2023-02-21 21:01 ET
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
2023-02-07 13:30 ET
Halozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results
2023-02-06 13:30 ET
Halozyme Appoints Barbara Duncan to its Board of Directors
2023-01-11 13:30 ET
HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024
2023-01-10 22:15 ET
Halozyme Provides 2023 Financial Guidance and Outlook
2023-01-03 13:30 ET
Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-11-09 13:30 ET
Halozyme to Participate in Upcoming Investor Conferences
2022-11-08 21:01 ET
HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
2022-10-25 12:30 ET
Halozyme to Report Third Quarter 2022 Financial and Operating Results
2022-09-01 12:30 ET
Halozyme to Participate in the 2022 Wells Fargo Healthcare Conference
2022-08-16 02:32 ET
Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028
2022-08-15 11:00 ET
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028
2022-08-09 20:01 ET
HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS
2022-08-02 04:55 ET
Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer
2022-07-26 12:30 ET
Halozyme to Report Second Quarter 2022 Financial and Operating Results
2022-06-08 12:30 ET
Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
2022-06-07 12:30 ET
Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy
2022-05-24 12:30 ET
Halozyme Completes Antares Pharma Acquisition
2022-05-12 12:00 ET
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma
2022-05-10 20:01 ET
Halozyme Reports First Quarter 2022 Results
2022-05-03 18:20 ET
Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call
2022-04-26 12:00 ET
HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA
2022-04-13 10:00 ET
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
2022-03-24 12:00 ET
Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology
2022-03-22 06:15 ET
Positive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod Using ENHANZE® Drug Delivery Technology for Generalized Myasthenia Gravis
2022-03-15 20:01 ET
Halozyme Appoints Moni Miyashita to Board of Directors
2022-02-22 21:01 ET
HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS
2022-02-09 13:00 ET
HALOZYME TO HOST FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL
2022-02-02 21:43 ET
Halozyme Appoints New Chief Financial Officer
2022-01-10 13:00 ET
HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK
2022-01-04 13:00 ET
Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference
2021-12-13 21:05 ET
HALOZYME APPOINTS NEW GENERAL COUNSEL
2021-12-09 21:01 ET
HALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE REPURCHASE PROGRAM
2021-12-01 19:21 ET
Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
2021-11-18 14:00 ET
Halozyme to Present at Upcoming Investor Conferences
2021-11-02 20:01 ET
Halozyme Reports Third Quarter 2021 Results
2021-10-19 20:05 ET
Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call
2021-09-15 20:05 ET
Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference
2021-08-26 13:00 ET
Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference
2021-08-09 20:01 ET
Halozyme Reports Second Quarter 2021 Results
2021-07-30 12:00 ET
Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference
2021-07-27 20:05 ET
Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference Call
2021-06-22 17:48 ET
Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma
2021-06-22 06:22 ET
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
2021-06-22 06:18 ET
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
2021-06-01 20:01 ET
Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
2021-05-28 20:40 ET
Halozyme to Present at Upcoming Investor Conferences
2021-05-21 14:02 ET
Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®
2021-05-10 20:01 ET
Halozyme Reports First Quarter 2021 Results
2021-04-29 20:05 ET
Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference
2021-04-20 20:05 ET
Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call
2021-02-25 03:41 ET
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027
2021-02-23 21:10 ET
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
2021-02-23 21:01 ET
Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results
2021-02-10 21:05 ET
Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call
2021-01-15 22:30 ET
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis
2021-01-11 13:00 ET
Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth
2021-01-04 13:00 ET
Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference
2020-11-23 13:05 ET
Halozyme Raises Full Year 2020 Guidance
2020-11-23 13:00 ET
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
2020-11-23 13:00 ET
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
2020-11-18 21:01 ET
Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-13 14:59 ET
Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer
2020-11-05 23:40 ET
MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&P SmallCap 600
2020-11-05 13:15 ET
Halozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE®
2020-11-02 21:01 ET
Halozyme Reports Third Quarter 2020 Results And Raises Full Year 2020 Guidance
2020-10-22 12:00 ET
Halozyme To Host THIRD Quarter 2020 Financial Results webcast and Conference Call
2020-10-06 06:14 ET
Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology
2020-09-17 12:00 ET
Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze® In Non-Small Cell Lung Cancer
2020-09-10 12:02 ET
Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis
2020-09-09 12:01 ET
Halozyme To Present At Upcoming Virtual Investor Conferences
2020-09-02 20:01 ET
Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference
2020-08-10 20:01 ET
Halozyme Reports Significant Recent Achievements And Second Quarter 2020 Results
2020-08-04 20:05 ET
Halozyme To Present At Canaccord Genuity 40th Annual Growth Conference
2020-07-29 20:05 ET
Halozyme To Host Second Quarter 2020 Financial Results Webcast And Conference Call
2020-06-29 16:54 ET
Halozyme Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer
2020-06-22 12:00 ET
Halozyme To Receive $10 Million Milestone Payment From Janssen
2020-06-17 21:08 ET
Halozyme To Participate In The BMO 2020 Prescriptions For Success Healthcare Conference
2020-06-13 11:09 ET
Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress
2020-06-04 16:35 ET
Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma
2020-05-28 12:01 ET
Halozyme To Present At Upcoming Virtual Investor Conferences
2020-05-14 20:01 ET
Halozyme To Receive $15 Million Milestone Payment From Janssen
2020-05-11 20:01 ET
Halozyme Reports First Quarter 2020 Results
2020-05-07 12:01 ET
Halozyme To Present At The Bank Of America Securities 2020 Healthcare Conference
2020-05-01 19:16 ET
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO™ Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma
2020-04-30 20:56 ET
Halozyme Announces Janssen's Receipt Of CHMP Positive Opinion For DARZALEX® Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
2020-04-28 21:05 ET
Halozyme To Host First Quarter 2020 Financial Results Webcast and Conference Call
2020-04-27 01:40 ET
Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
2020-04-03 12:00 ET
Halozyme Announces Change Of Location Of Annual Stockholders' Meeting
2020-02-26 21:01 ET
Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference
2020-02-25 06:20 ET
Halozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology
2020-02-24 21:02 ET
Halozyme Reports Fourth Quarter and Full Year 2019 Results
2020-02-24 21:01 ET
Halozyme Announces CFO Transition
2020-02-10 21:01 ET
Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call
2020-01-14 13:00 ET
Halozyme Provides 2020 Business Update And Financial Guidance
2020-01-14 13:00 ET
Halozyme Provides 2020 Business Update And Financial Guidance
2020-01-03 13:00 ET
Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference
2019-12-12 07:00 ET
Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium
2019-11-14 03:57 ET
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024
2019-11-12 21:10 ET
Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024
2019-11-12 21:01 ET
Halozyme Reports Third Quarter 2019 Results
2019-11-04 12:00 ET
Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint
2019-11-04 12:00 ET
Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology
2019-10-21 12:00 ET
Halozyme To Host Third Quarter 2019 Financial Results Webcast And Conference Call
2019-09-23 12:00 ET
Halozyme To Participate In 2019 Cantor Global Healthcare Conference
2019-09-13 05:00 ET
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology
2019-08-06 20:01 ET
Halozyme Reports Second Quarter 2019 Results
2019-07-25 12:00 ET
Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference
2019-07-23 20:01 ET
Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call
2019-07-19 11:00 ET
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
2019-07-17 12:00 ET
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology
2019-07-12 15:59 ET
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
2019-06-25 12:00 ET
Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology
2019-06-04 12:00 ET
Halozyme To Participate In Upcoming Investor Conferences
2019-05-22 05:05 ET
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement
2019-05-13 12:01 ET
Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019
2019-04-23 20:01 ET
Halozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call

SEC forms

Show financial reports only

SEC form 10
2024-02-20 16:07 ET
Halozyme Therapeutics reported for 2023 q4
SEC form 8
2024-02-20 16:03 ET
Halozyme Therapeutics published news for 2023 q4
SEC form 8
2024-02-20 16:03 ET
Halozyme Therapeutics published news for 2023 q4
SEC form 10
2024-02-20 00:00 ET
Halozyme Therapeutics published news for 2023 q4
SEC form 8
2024-01-17 00:00 ET
Halozyme Therapeutics published news for 2023 q4
SEC form 10
2023-11-06 16:07 ET
Halozyme Therapeutics reported for 2023 q3
SEC form 8
2023-11-06 16:04 ET
Halozyme Therapeutics published news for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Halozyme Therapeutics published news for 2023 q3
SEC form 10
2023-08-08 16:10 ET
Halozyme Therapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:06 ET
Halozyme Therapeutics published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Halozyme Therapeutics published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Halozyme Therapeutics published news for 2023 q2
SEC form 10
2023-05-09 00:00 ET
Halozyme Therapeutics published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Halozyme Therapeutics published news for 2023 q1
SEC form 6
2023-03-15 18:28 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 6
2023-03-13 08:47 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 6
2023-02-23 16:05 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 10
2023-02-21 16:27 ET
Halozyme Therapeutics reported for 2022 q4
SEC form 6
2023-02-21 16:21 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 8
2023-02-21 00:00 ET
Halozyme Therapeutics reported for 2022 q4
SEC form 10
2023-02-21 00:00 ET
Halozyme Therapeutics reported for 2022 q4
SEC form 6
2023-02-06 17:19 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 6
2023-02-06 16:03 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 6
2023-01-10 17:16 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 8
2023-01-10 00:00 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 10
2022-11-08 16:10 ET
Halozyme Therapeutics reported for 2022 q3
SEC form 6
2022-11-08 16:06 ET
Halozyme Therapeutics published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Halozyme Therapeutics reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Halozyme Therapeutics reported for 2022 q3
SEC form 6
2022-08-19 17:23 ET
Halozyme Therapeutics published news for 2022 q2
SEC form 6
2022-08-18 17:14 ET
Halozyme Therapeutics published news for 2022 q2
SEC form 6
2022-08-16 08:42 ET
Halozyme Therapeutics published news for 2022 q2
SEC form 6
2022-08-15 07:18 ET
Halozyme Therapeutics published news for 2022 q2
SEC form 6
2022-08-09 16:13 ET
Halozyme Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 16:12 ET
Halozyme Therapeutics reported for 2022 q2
SEC form 6
2022-08-09 16:08 ET
Halozyme Therapeutics published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Halozyme Therapeutics reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Halozyme Therapeutics reported for 2022 q2
SEC form 6
2022-05-24 16:16 ET
Halozyme Therapeutics published news for 2022 q1
SEC form 10
2022-05-10 16:15 ET
Halozyme Therapeutics reported for 2022 q1
SEC form 6
2022-05-10 16:07 ET
Halozyme Therapeutics published news for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Halozyme Therapeutics reported for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Halozyme Therapeutics reported for 2022 q1
SEC form 6
2022-05-06 16:10 ET
Halozyme Therapeutics published news for 2022 q1
SEC form 6
2022-04-13 17:18 ET
Halozyme Therapeutics published news for 2022 q1
SEC form 6
2022-03-25 16:31 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 6
2022-03-21 16:11 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 6
2022-03-15 16:50 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 10
2022-02-22 16:21 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 6
2022-02-22 16:06 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 10
2022-02-22 00:00 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 8
2022-02-22 00:00 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 6
2022-02-03 16:12 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 6
2022-01-10 08:12 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 6
2021-12-29 16:15 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 6
2021-12-13 17:10 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 6
2021-12-10 16:08 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 6
2021-11-02 17:03 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 10
2021-11-02 16:09 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 6
2021-11-02 16:03 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 10
2021-08-09 16:07 ET
Halozyme Therapeutics published news for 2021 q2
SEC form 6
2021-08-09 16:02 ET
Halozyme Therapeutics published news for 2021 q2
SEC form 8
2021-08-09 00:00 ET
Halozyme Therapeutics published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Halozyme Therapeutics published news for 2021 q2
SEC form 10
2021-05-10 16:08 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 6
2021-05-10 16:03 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 6
2021-05-07 16:31 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 6
2021-05-05 16:01 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 6
2021-05-03 16:03 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 6
2021-03-26 16:04 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 6
2021-03-01 16:06 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 6
2021-02-25 06:06 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 6
2021-02-23 16:16 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 10
2021-02-23 16:12 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 6
2021-02-23 16:03 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 6
2021-01-13 17:11 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 08:07 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 10
2020-11-02 16:11 ET
Halozyme Therapeutics published news for 2020 q3
SEC form 6
2020-11-02 16:04 ET
Halozyme Therapeutics published news for 2020 q3